Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page URLs for STN Seminar Schedule - N. America
     1
NEWS
                 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAplus records now contain indexing from 1907 to the
                 present
NEWS 4 AUG 05
                New pricing for EUROPATFULL and PCTFULL effective
                August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18
                Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
             MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
             AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS
             STN Operating Hours Plus Help Desk Availability
NEWS INTER
             General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN
             CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:58:30 ON 24 NOV 2003

=> file polymers COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'APOLLIT' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 10:58:43 ON 24 NOV 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 10:58:43 ON 24 NOV 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 10:58:43 ON 24 NOV 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 10:58:43 ON 24 NOV 2003 Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT 2003 THOMSON ISI

FILE 'TEXTILETECH' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 10:58:43 ON 24 NOV 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:58:43 ON 24 NOV 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 10:58:43 ON 24 NOV 2003 COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 10:58:43 ON 24 NOV 2003

```
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
 => s hypertrop?
        137326 HYPERTROP?
 => s l1 and myocardial
          26539 L1 AND MYOCARDIAL
 => s 12 and treat?
  19 FILES SEARCHED...
           9880 L2 AND TREAT?
 => s 13 and (calcium(w) channel or beta(w) blocker or i(w) channel)
   13 FILES SEARCHED...
   19 FILES SEARCHED...
           1370 L3 AND (CALCIUM(W) CHANNEL OR BETA(W) BLOCKER OR I(W) CHANNEL)
 => s 14 and pharmaceutical
            804 L4 AND PHARMACEUTICAL
 => s 15 and (zatebradine or cilobradine or alinidine)
              3 L5 AND (ZATEBRADINE OR CILOBRADINE OR ALINIDINE)
 => dis 16 1-3 bib abs
      ANSWER 1 OF 3 USPATFULL on STN
 AN
        2003:106216 USPATFULL
        NOVEL CALCIUM CHANNEL DRUGS AND USES
 TΙ
 IN
        JI, YU-HUA, REDWOOD CITY, CA, UNITED STATES
        NATARAJAN, MAYA, SAN DIEGO, CA, UNITED STATES
        GRIFFIN, JOHN H., ATHERTON, CA, UNITED STATES
        JENKINS, THOMAS E., LAHONDA, CA, UNITED STATES
PΙ
        US 2003073127
                        A1 20030417
ΑI
       US 1999-456429
                                19991208 (9)
                          A1
RLI
       Continuation-in-part of Ser. No. US 1999-325557, filed on 4 Jun 1999,
       ABANDONED
PRAI
       US 1998-88465P
                            19980608 (60)
       US 1998-93068P
                            19980716 (60)
       US 1998-103866P
                            19981012 (60)
DT
       Utility
FS
       APPLICATION
LREP
       THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
CLMN
       Number of Claims: 51
ECL
       Exemplary Claim: 1
DRWN
       26 Drawing Page(s)
LN.CNT 5977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Novel multibinding compounds are disclosed. The compounds of this
       invention comprise 2-10 ligands covalently connected, each of the
       ligands being capable of binding to a ligand binding site in a Ca.sup.++
       channel , thereby modulating the biological activities thereof.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L6
     ANSWER 2 OF 3 USPATFULL on STN
ΑN
       2003:65352 USPATFULL
TI
       Heart homing conjugates
IN
       Ruoslahti, Erkki, Rancho Santa Fe, CA, UNITED STATES
       MacKenna, Deidre A., San Diego, CA, UNITED STATES
PA
       The Burnham Institute (U.S. corporation)
PΙ
       US 2003045476
                         A1
                               20030306
AΤ
       US 2001-910582
                          A1
                               20010720 (9)
RI_{1}T
       Division of Ser. No. US 1999-326718, filed on 7 Jun 1999, GRANTED, Pat.
       No. US 6303573
DT
       Utility
```

```
FS
       APPLICATION
LREP
       CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN
       DIEGO, CA, 92122
CLMN
       Number of Claims: 34
ECL
       Exemplary Claim: 1
DRWN
       2 Drawing Page(s)
LN.CNT 1553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention provides a heart homing peptide that contains the
AΒ
       amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3);
       VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID
       NO: 10) and further provides conjugates in which a heart homing peptide
       is linked to a moiety such as a therapeutic agent. The conjugates of the
       invention are useful for treating cardiovascular diseases such
       as atherosclerosis and restenosis.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L<sub>1</sub>6
     ANSWER 3 OF 3 USPATFULL on STN
       2001:179068 USPATFULL
AN
ΤI
       Heart homing peptides and methods of using same
       Ruoslahti, Erkki, Rancho Santa Fe, CA, United States
TN
       MacKenna, Deidre A., San Diego, CA, United States
PΆ
       The Burnham Institute, La Jolla, CA, United States (U.S. corporation)
                        B1
PΙ
       US 6303573
                               20011016
ΑI
       US 1999-326718
                               19990607 (9)
рπ
       Utility
FS
       GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
       Campbell & Flores LLP
LREP
       Number of Claims: 27
CLMN
       Exemplary Claim: 1
ECL
DRWN
       4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AΒ
       The present invention provides a heart homing peptide that contains the
       amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3);
       VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID
       NO: 10) and further provides conjugates in which a heart homing peptide
       is linked to a moiety such as a therapeutic agent. The conjugates of the
       invention are useful for treating cardiovascular diseases such
       as atherosclerosis and restenosis.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
=> dis hist
     (FILE 'HOME' ENTERED AT 10:58:30 ON 24 NOV 2003)
     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT,
     JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH,
     USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 10:58:43 ON 24 NOV 2003
L1
         137326 S HYPERTROP?
L_2
          26539 S L1 AND MYOCARDIAL
L3
           9880 S L2 AND TREAT?
L4
           1370 S L3 AND (CALCIUM(W)CHANNEL OR BETA(W)BLOCKER OR I(W)CHANNEL)
L5
            804 S L4 AND PHARMACEUTICAL
L6
              3 S L5 AND (ZATEBRADINE OR CILOBRADINE OR ALINIDINE)
=> file medline, embase, biosis
COST IN U.S. DOLLARS
                                                  SINCE FILE
                                                                 TOTAL
                                                      ENTRY
                                                               SESSION
FULL ESTIMATED COST
                                                                 71.42
```

FILE 'MEDLINE' ENTERED AT 11:03:32 ON 24 NOV 2003

FILE 'EMBASE' ENTERED AT 11:03:32 ON 24 NOV 2003 COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:03:32 ON 24 NOV 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s l1 and l2 and l3 and l4 and l5 and l6 2 FILES SEARCHED...

L7 0 L1 AND L2 AND L3 AND L4 AND L5 AND L6

=> file polymers
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 2.38 73.80

FULL ESTIMATED COST

FILE 'APOLLIT' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 11:04:48 ON 24 NOV 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 11:04:48 ON 24 NOV 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 11:04:48 ON 24 NOV 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 11:04:48 ON 24 NOV 2003 Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:04:48 ON 24 NOV 2003

COPYRIGHT (C) 2003 RAPRA Technology Ltd. FILE 'SCISEARCH' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT 2003 THOMSON ISI FILE 'TEXTILETECH' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 Inst. of Textile Technology FILE 'USPATFULL' ENTERED AT 11:04:48 ON 24 NOV 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'USPAT2' ENTERED AT 11:04:48 ON 24 NOV 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'WPIDS' ACCESS NOT AUTHORIZED FILE 'WPINDEX' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 THOMSON DERWENT FILE 'WTEXTILES' ENTERED AT 11:04:48 ON 24 NOV 2003 COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved. => s 13 and (zatebradine or cilobradine or alinidine) 5 L3 AND (ZATEBRADINE OR CILOBRADINE OR ALINIDINE) => dis 18 1-5 bib abs L8ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN AN2001:780659 CAPLUS DN 135:335152 Use of bradycardiac substances in the treatment of TΤ myocardial diseases associated with hypertrophy and novel drug combinations Daemmgen, Juergen; Guth, Brian; Seidler, Randolph IN PΑ Boehringer Ingelheim Pharma K.-G., Germany SO PCT Int. Appl., 13 pp. CODEN: PIXXD2 DT Patent LA German FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----______ PΙ WO 2001078699 A2 20011025 WO 2001-EP4034 20010407 WO 2001078699 A3 20020620 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG A1 20011025 DE 2000-10018401 20000413 EP 2001-949281 20010407 DE 10018401 20030122 EP 1276476 A2 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR BR 2001009996 A 20030527 BR 2001-9996 20010407 A 20030430 BG 107103 BG 2002-107103 20020913 NO 2002004924 A 20021011 NO 2002-4924 20021011

AB The invention relates to a novel use of bradycardiac substances such as a Ca++ channel blocker, beta-receptor blockers or if channel blockers, the if channel blockers being preferred. The substances are optionally used

PRAI DE 2000-10018401 A 20000413 WO 2001-EP4034 W 20010407

particular for treating idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic animals. Thus 1.25 mg cilobradine was encapsulated in capsules that were prepared from 82.75 mg lactose monohydrate and 55.3 mg corn starch. ANSWER 2 OF 5 USPATFULL on STN ΑN 2003:106216 USPATFULL TΙ NOVEL CALCIUM CHANNEL DRUGS AND USES IN JI, YU-HUA, REDWOOD CITY, CA, UNITED STATES NATARAJAN, MAYA, SAN DIEGO, CA, UNITED STATES GRIFFIN, JOHN H., ATHERTON, CA, UNITED STATES JENKINS, THOMAS E., LAHONDA, CA, UNITED STATES A1 20030417 PΙ US 2003073127 ΑI US 1999-456429 A1 19991208 (9) Continuation-in-part of Ser. No. US 1999-325557, filed on 4 Jun 1999, RLI ABANDONED PRAI US 1998-88465P 19980608 (60) US 1998-93068P 19980716 (60) US 1998-103866P 19981012 (60) DTUtility FS APPLICATION LREP THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 CLMN Number of Claims: 51 ECL Exemplary Claim: 1 DRWN 26 Drawing Page(s) LN.CNT 5977 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Novel multibinding compounds are disclosed. The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca.sup.++ channel , thereby modulating the biological activities thereof. CAS INDEXING IS AVAILABLE FOR THIS PATENT. L8 ANSWER 3 OF 5 USPATFULL on STN AN 2003:65352 USPATFULL TIHeart homing conjugates IN Ruoslahti, Erkki, Rancho Santa Fe, CA, UNITED STATES MacKenna, Deidre A., San Diego, CA, UNITED STATES PΑ The Burnham Institute (U.S. corporation) PΙ US 2003045476 Αl 20030306 ΑI US 2001-910582 Α1 20010720 (9) RLI Division of Ser. No. US 1999-326718, filed on 7 Jun 1999, GRANTED, Pat. No. US 6303573 DTUtility FS APPLICATION CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN LREP DIEGO, CA, 92122 CLMN Number of Claims: 34 ECL Exemplary Claim: 1 DRWN 2 Drawing Page(s) LN.CNT 1553 CAS INDEXING IS AVAILABLE FOR THIS PATENT. The present invention provides a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating cardiovascular diseases such

in combination with a cardio-active substance for inducing the regression

of myocardial diseases associated with hypertrophy, in

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

as atherosclerosis and restenosis.

```
L8
     ANSWER 4 OF 5 USPATFULL on STN
 AN
        2001:179068 USPATFULL
 ΤI
        Heart homing peptides and methods of using same
        Ruoslahti, Erkki, Rancho Santa Fe, CA, United States
 ΤN
        MacKenna, Deidre A., San Diego, CA, United States
 PA
        The Burnham Institute, La Jolla, CA, United States (U.S. corporation)
 PΙ
        US 6303573
                        B1
                               20011016
ΑI
       US 1999-326718
                                19990607 (9)
 DT
       Utility
 FS
       GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP
       Campbell & Flores LLP
CLMN
       Number of Claims: 27
ECL
       Exemplary Claim: 1
DRWN
       4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The present invention provides a heart homing peptide that contains the
       amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3);
       VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID
       NO: 10) and further provides conjugates in which a heart homing peptide
       is linked to a moiety such as a therapeutic agent. The conjugates of the
       invention are useful for treating cardiovascular diseases such
       as atherosclerosis and restenosis.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 5 OF 5 WPINDEX COPYRIGHT 2003 THOMSON DERWENT on STN
L8
     2002-011919 [02]
AN
                        WPINDEX
DNC C2002-003158
TI
     Medicament for treating hypertrophy-related
     myocardial disease, containing bradycardic agent, preferably
     cilobradine, and optionally another cardiac drug.
DC
ΙN
     DAEMMGEN, J; GUTH, B; SEIDLER, R
PΑ
     (BOEH) BOEHRINGER INGELHEIM PHARMA KG; (BOEH) BOEHRINGER INGELHEIM PHARMA
     GMBH & CO KG
CYC
     DE 10018401
PΙ
                  A1 20011025 (200202)*
     WO 2001078699 A2 20011025 (200202) DE
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TR TZ UG ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
            LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
            SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
     AU 2001070484 A 20011030 (200219)
     NO 2002004924 A 20021011 (200304)
     EP 1276476
                 A2 20030122 (200308) DE
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI TR
     SK 2002001458 A3 20030304 (200321)
     KR 2002089453 A 20021129 (200322)
     CZ 2002003752 A3 20030312 (200324)
     BR 2001009996 A 20030527 (200344)
     CN 1422153
                 A 20030604 (200356)
     HU 2003000917 A2 20030828 (200363)
ADT DE 10018401 A1 DE 2000-10018401 20000413; WO 2001078699 A2 WO 2001-EP4034
     20010407; AU 2001070484 A AU 2001-70484 20010407; NO 2002004924 A WO
     2001-EP4034 20010407, NO 2002-4924 20021011; EP 1276476 A2 EP 2001-949281
     20010407, WO 2001-EP4034 20010407; SK 2002001458 A3 WO 2001-EP4034
     20010407, SK 2002-1458 20010407; KR 2002089453 A KR 2002-713688 20021011;
    CZ 2002003752 A3 WO 2001-EP4034 20010407, CZ 2002-3752 20010407; BR
     2001009996 A BR 2001-9996 20010407, WO 2001-EP4034 20010407; CN 1422153 A
    CN 2001-807959 20010407; HU 2003000917 A2 WO 2001-EP4034 20010407, HU
```

2003-917 20010407 FDT AU 2001070484 A Based on WO 2001078699; EP 1276476 A2 Based on WO 2001078699; SK 2002001458 A3 Based on WO 2001078699; CZ 2002003752 A3 Based on WO 2001078699; BR 2001009996 A Based on WO 2001078699; HU 2003000917 A2 Based on WO 2001078699 PRAI DE 2000-10018401 20000413 AN 2002-011919 [02] WPINDEX AΒ DE 10018401 A UPAB: 20020109 NOVELTY - A medicament (A) for treating myocardial diseases associated with hypertrophy contains a bradycardic agent (I) and optionally another cardiac drug (II). ACTIVITY - Cardiant. In tests in a cat having severe hypertrophic cardiomyopathy, oral administration of cilobradine (Ia) twice daily at 0.3 mg/kg marked reduced the clinical symptoms (e.g. by reducing pain and normalizing the ECG) and also caused regression of the myocardial hypertrophy after 1 and 2 years. MECHANISM OF ACTION - Calcium ion channel blocker; beta -receptor blocker; if channel blocker. USE - (A) is used for treating myocardial diseases associated with hypertrophy (claimed), especially idiopathic hypertrophic cardiomyopathy such as hypertrophy of the remaining myocardium after cardiac infarction, ischemic cardiomyopathy, valve-associated hypertrophy of the myocardium or myocarditis due to toxic or iatrogenic effects. ADVANTAGE - As well as alleviating the clinical symptoms, (A) causes regression of the above severe heart conditions. if Channel blockers (I) inhibit rebound increase in cardiac frequency, and have a synergistic effect in combination with (II). Dwq.0/0 => dis hist (FILE 'HOME' ENTERED AT 10:58:30 ON 24 NOV 2003) FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 10:58:43 ON 24 NOV 2003 L1 137326 S HYPERTROP? 26539 S L1 AND MYOCARDIAL L2 L3 9880 S L2 AND TREAT? L41370 S L3 AND (CALCIUM(W) CHANNEL OR BETA(W) BLOCKER OR I(W) CHANNEL) L5 804 S L4 AND PHARMACEUTICAL L6 3 S L5 AND (ZATEBRADINE OR CILOBRADINE OR ALINIDINE) FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:03:32 ON 24 NOV 2003 L7 0 S L1 AND L2 AND L3 AND L4 AND L5 AND L6 FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 11:04:48 ON 24 NOV 2003 5 S L3 AND (ZATEBRADINE OR CILOBRADINE OR ALINIDINE) L8=> ---Logging off of STN---Executing the logoff script...

COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY 42.68 FULL ESTIMATED COST 116.48 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY CA SUBSCRIBER PRICE -0.65 -0.65

STN INTERNATIONAL LOGOFF AT 11:06:31 ON 24 NOV 2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sss1623pta

PASSWORD:

LOGINID/PASSWORD REJECTED

The loginid and/or password sent to STN were invalid. You either typed them incorrectly, or line noise may have corrupted them.

Do you wish to retry the logon? Enter choice (y/N):

Connecting via Winsock to STN

LOGINID:

ssspta1623kxg

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2